Getting closer to affective disorders: The role of CRH receptor systems

Marianne B. Müller; Wolfgang Wurst

doi:10.1016/j.molmed.2004.06.007

Getting closer to affective disorders: The role of CRH receptor systems

Marianne B. Müller, Wolfgang Wurst

Research output: Contribution to journal › Review article › peer-review

74 Scopus citations

Abstract

Depressive disorders are a leading cause of morbidity and mortality worldwide. Current antidepressant drugs targeting monoamine neurotransmitter systems have a delayed onset of action, and fewer than 50% of the patients attain complete remission after therapy with a single antidepressant. A large body of preclinical and clinical evidence points to a key role of the corticotropin-releasing hormone (CRH) receptor 1 subtype (CRHR1) in mediating CRH-elicited effects in anxiety, depressive disorders and stress-associated pathologies. Genetic modification of CRHR1 function in mice by the use of conventional and conditional knockout strategies enables further analysis of specific elements in the CRH circuitry. The recent characterisation of several selective small-molecule CRHR1 antagonists offers new possibilities for the treatment of anxiety and depression.

Original language	English
Pages (from-to)	409-415
Number of pages	7
Journal	Trends in Molecular Medicine
Volume	10
Issue number	8
DOIs	https://doi.org/10.1016/j.molmed.2004.06.007
State	Published - 1 Aug 2004
Externally published	Yes

Access to Document

10.1016/j.molmed.2004.06.007

Cite this

@article{d1eba5af5252416a96887c9d56f78587,

title = "Getting closer to affective disorders: The role of CRH receptor systems",

abstract = "Depressive disorders are a leading cause of morbidity and mortality worldwide. Current antidepressant drugs targeting monoamine neurotransmitter systems have a delayed onset of action, and fewer than 50% of the patients attain complete remission after therapy with a single antidepressant. A large body of preclinical and clinical evidence points to a key role of the corticotropin-releasing hormone (CRH) receptor 1 subtype (CRHR1) in mediating CRH-elicited effects in anxiety, depressive disorders and stress-associated pathologies. Genetic modification of CRHR1 function in mice by the use of conventional and conditional knockout strategies enables further analysis of specific elements in the CRH circuitry. The recent characterisation of several selective small-molecule CRHR1 antagonists offers new possibilities for the treatment of anxiety and depression.",

author = "M{\"u}ller, {Marianne B.} and Wolfgang Wurst",

year = "2004",

month = aug,

day = "1",

doi = "10.1016/j.molmed.2004.06.007",

language = "English",

volume = "10",

pages = "409--415",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd.",

number = "8",

}

TY - JOUR

T1 - Getting closer to affective disorders

T2 - The role of CRH receptor systems

AU - Müller, Marianne B.

AU - Wurst, Wolfgang

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Depressive disorders are a leading cause of morbidity and mortality worldwide. Current antidepressant drugs targeting monoamine neurotransmitter systems have a delayed onset of action, and fewer than 50% of the patients attain complete remission after therapy with a single antidepressant. A large body of preclinical and clinical evidence points to a key role of the corticotropin-releasing hormone (CRH) receptor 1 subtype (CRHR1) in mediating CRH-elicited effects in anxiety, depressive disorders and stress-associated pathologies. Genetic modification of CRHR1 function in mice by the use of conventional and conditional knockout strategies enables further analysis of specific elements in the CRH circuitry. The recent characterisation of several selective small-molecule CRHR1 antagonists offers new possibilities for the treatment of anxiety and depression.

AB - Depressive disorders are a leading cause of morbidity and mortality worldwide. Current antidepressant drugs targeting monoamine neurotransmitter systems have a delayed onset of action, and fewer than 50% of the patients attain complete remission after therapy with a single antidepressant. A large body of preclinical and clinical evidence points to a key role of the corticotropin-releasing hormone (CRH) receptor 1 subtype (CRHR1) in mediating CRH-elicited effects in anxiety, depressive disorders and stress-associated pathologies. Genetic modification of CRHR1 function in mice by the use of conventional and conditional knockout strategies enables further analysis of specific elements in the CRH circuitry. The recent characterisation of several selective small-molecule CRHR1 antagonists offers new possibilities for the treatment of anxiety and depression.

UR - http://www.scopus.com/inward/record.url?scp=4043163435&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2004.06.007

DO - 10.1016/j.molmed.2004.06.007

M3 - Review article

C2 - 15310462

AN - SCOPUS:4043163435

SN - 1471-4914

VL - 10

SP - 409

EP - 415

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 8

ER -

Getting closer to affective disorders: The role of CRH receptor systems

Abstract

Access to Document

Other files and links

Fingerprint

Cite this